After being called out on some intellectual property claims late last year, Teva has fallen victim to the Federal Trade Commission’s (FTC’s) ongoing crusade against questionable drug patents.
Two prominent congressional Democrats this week wrote to eight pharmaceutical company CEOs, urging them to remove 130 patents ...
The government has a variety of strategies to protect the public from price-gouging and information advantages over the ...
“There is no dispute that the Inhaler Patents contain no claim for the active ingredient at issue, albuterol sulfate. Amneal contends that the Inhaler Patents do not meet the requirement that ...
We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins Some states have laws and ethical rules regarding solicitation and ...
, opens new tab with the backing of the U.S. Federal Trade Commission convinced a New Jersey federal court on Monday to remove five Teva Pharmaceutical (TEVA.TA) , opens new tab patents from a U.S ...
Opinions expressed by Forbes Contributors are their own. The narrative around so-called junk fees, as the regulators began contemplating new restrictions, seemed to define the target as extra ...
It’s hard to find bipartisan consensus among lawmakers in Congress these days. But there’s widespread agreement on calls for pharmaceutical patent reform. The steep prices of brand-name drugs ...
It seems it’s not only the Biden administration that believes regulating “junk fees” is popular with voters. Minnesota joins California as states that have passed their own junk fee legislation.
Congressional Democrats aiming to reduce drug prices are targeting 130 patents, including some from the pharmaceutical company Novo Nordisk related to the expensive drug Ozempic. (Bloomberg/Getty ...